Journal
BLOOD
Volume 132, Issue 1, Pages 31-39Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-01-785998
Keywords
-
Categories
Funding
- National Institutes of Health, National Cancer Institute through the CLL Research Consortium [PO1-CA081534]
Ask authors/readers for more resources
Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available